AVDL vs. MRUS, ACAD, ACLX, SWTX, RARE, PTGX, SRRK, ALVO, MTSR, and CPRX
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), Protagonist Therapeutics (PTGX), Scholar Rock (SRRK), Alvotech (ALVO), Metsera (MTSR), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry.
Avadel Pharmaceuticals vs.
Avadel Pharmaceuticals (NASDAQ:AVDL) and Merus (NASDAQ:MRUS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment, community ranking and earnings.
Merus has lower revenue, but higher earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Merus, indicating that it is currently the more affordable of the two stocks.
Avadel Pharmaceuticals has a net margin of -52.53% compared to Merus' net margin of -680.61%. Merus' return on equity of -38.89% beat Avadel Pharmaceuticals' return on equity.
Merus received 16 more outperform votes than Avadel Pharmaceuticals when rated by MarketBeat users. Likewise, 67.96% of users gave Merus an outperform vote while only 66.60% of users gave Avadel Pharmaceuticals an outperform vote.
69.2% of Avadel Pharmaceuticals shares are held by institutional investors. Comparatively, 96.1% of Merus shares are held by institutional investors. 4.8% of Avadel Pharmaceuticals shares are held by insiders. Comparatively, 4.6% of Merus shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Avadel Pharmaceuticals had 3 more articles in the media than Merus. MarketBeat recorded 10 mentions for Avadel Pharmaceuticals and 7 mentions for Merus. Avadel Pharmaceuticals' average media sentiment score of 0.93 beat Merus' score of 0.85 indicating that Avadel Pharmaceuticals is being referred to more favorably in the media.
Avadel Pharmaceuticals currently has a consensus price target of $19.43, indicating a potential upside of 89.92%. Merus has a consensus price target of $85.83, indicating a potential upside of 52.05%. Given Avadel Pharmaceuticals' higher possible upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Merus.
Avadel Pharmaceuticals has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Merus has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.
Summary
Merus beats Avadel Pharmaceuticals on 10 of the 19 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AVDL) was last updated on 6/11/2025 by MarketBeat.com Staff
